Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A short course of omalizumab (Xolair) before oral immunotherapy (OIT) allowed 97% of food-allergic patients to jump straight to daily maintenance dosing — skipping the traditional, visit-heavy up-dosing process. In a prospective study of 100 children and young adults, 84% started at target doses for all their food allergens. Adverse events were common but mostly mild, with only 2% discontinuing therapy.
Skipping the slow climb: Omalizumab paves a faster path to food allergy OIT
A new prospective study published in Annals of Allergy, Asthma & Immunology shows that a brief pretreatment course of omalizumab (Xolair) can dramatically streamline oral immunotherapy (OIT) for food-allergic patients. In a cohort of 100 children and young adults (median age 9), those who received at least 8 weeks of omalizumab before OIT were able to skip the traditional multi-step dose escalation process — jumping directly to low maintenance doses after just a two-dose initiation challenge.
The results were striking: 97% of patients started daily OIT maintenance dosing for at least one food allergen, and 84% started at target doses for all their allergens. The simplified protocol cut the typical 10–11 clinic visits needed to reach maintenance down to just 1–2 visits.
By the Numbers
Why it matters: Traditional OIT is burdensome — requiring frequent clinic visits over months. This omalizumab-facilitated protocol offers a faster, more tolerable path to food allergy protection, which could meaningfully improve access and adherence for families. Longer-term follow-up studies are still needed to confirm durability.
